Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$797.45 USD

797.45
4,519,686

+21.07 (2.71%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $798.17 +0.72 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla

Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sweta Killa headshot

Eli Lilly Beats on Q3 Earnings: ETFs to Buy

Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.

Company News for Nov 03, 2023

Companies In The Article: LLY, SBUX, SHOP, CYBR

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Tracey Ryniec headshot

5 Hot Earnings Charts

These 5 companies have red hot charts and they have outstanding earnings surprise histories.

Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 46.88% and 3.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Pre-Markets in Green to Start a Crucial Week of Events

Pre-Markets in Green to Start a Crucial Week of Events.

Mark Vickery headshot

Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3

Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products

Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh

Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

Merck (MRK) delivered earnings and revenue surprises of 9.79% and 3.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?

On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.

Eli Lilly (LLY) Stock Moves -1.01%: What You Should Know

Eli Lilly (LLY) closed at $586.46 in the latest trading session, marking a -1.01% move from the prior day.

Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?

Smart Beta ETF report for QUS

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS